136 related articles for article (PubMed ID: 33503492)
1. Toxicity studies of highly bioavailable isoniazid loaded solid lipid nanoparticles as per Organisation for Economic Co-operation and Development (OECD) guidelines.
Bhandari R; Singh M; Jindal S; Kaur IP
Eur J Pharm Biopharm; 2021 Mar; 160():82-91. PubMed ID: 33503492
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles.
Bhandari R; Kaur IP
Int J Pharm; 2013 Jan; 441(1-2):202-12. PubMed ID: 23220081
[TBL] [Abstract][Full Text] [Related]
3. Streptomycin sulphate loaded solid lipid nanoparticles show enhanced uptake in macrophage, lower MIC in Mycobacterium and improved oral bioavailability.
Singh M; Schiavone N; Papucci L; Maan P; Kaur J; Singh G; Nandi U; Nosi D; Tani A; Khuller GK; Priya M; Singh R; Kaur IP
Eur J Pharm Biopharm; 2021 Mar; 160():100-124. PubMed ID: 33497794
[TBL] [Abstract][Full Text] [Related]
4. Encapsulating Rifampicin into SLNs: A Viable Option for Managing its Bioavailability Issues Upon Co-Delivery with Isoniazid.
Singh H; Sood R; Chaira T; Khanna A; Upadhaya DJ; Bambal R; Bhatnagar PK; Singh M; Kaur IP
Curr Drug Deliv; 2020; 17(4):343-347. PubMed ID: 32077827
[TBL] [Abstract][Full Text] [Related]
5. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety.
Singh H; Jindal S; Singh M; Sharma G; Kaur IP
Int J Pharm; 2015 May; 485(1-2):138-51. PubMed ID: 25769294
[TBL] [Abstract][Full Text] [Related]
6. Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles.
Xie S; Wang F; Wang Y; Zhu L; Dong Z; Wang X; Li X; Zhou W
Part Fibre Toxicol; 2011 Nov; 8():33. PubMed ID: 22098626
[TBL] [Abstract][Full Text] [Related]
7. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis.
Dutt M; Khuller GK
Int J Antimicrob Agents; 2001 Feb; 17(2):115-22. PubMed ID: 11165115
[TBL] [Abstract][Full Text] [Related]
8. Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression of transporter Mrp2, Ntcp, and Oatp1a4 in liver.
Zhou L; Song Y; Zhao J; Qin H; Zhang G; Zhou Y; Wu X
Pharm Biol; 2016; 54(6):931-7. PubMed ID: 26987268
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel.
Shi LL; Lu J; Cao Y; Liu JY; Zhang XX; Zhang H; Cui JH; Cao QR
Drug Dev Ind Pharm; 2017 May; 43(5):839-846. PubMed ID: 27487431
[TBL] [Abstract][Full Text] [Related]
10. Rifampicin-loaded 'flower-like' polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid.
Moretton MA; Hocht C; Taira C; Sosnik A
Nanomedicine (Lond); 2014 Aug; 9(11):1635-50. PubMed ID: 24410279
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of oral lipid nanoparticle formulations (LNFs) for chemical stabilization of antitubercular drugs: physicochemical and cellular evaluation.
Banerjee S; Roy S; Nath Bhaumik K; Kshetrapal P; Pillai J
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):540-558. PubMed ID: 29373927
[TBL] [Abstract][Full Text] [Related]
12. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2406-17. PubMed ID: 21491451
[TBL] [Abstract][Full Text] [Related]
13. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
14. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis.
Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Dec; 44(12):1975-1989. PubMed ID: 30058392
[TBL] [Abstract][Full Text] [Related]
15. Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice.
Thakkar A; Chenreddy S; Thio A; Khamas W; Wang J; Prabhu S
Int J Nanomedicine; 2016; 11():3265-76. PubMed ID: 27499621
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Oral Absorption of All-trans Retinoic Acid upon Encapsulation in Solid Lipid Nanoparticles.
Kumar M; Sharma G; Singla D; Singh S; Kakkar V; Gulati JS; Kaur IP
Pharm Nanotechnol; 2020; 8(6):495-510. PubMed ID: 33115399
[TBL] [Abstract][Full Text] [Related]
17. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
Pandey R; Sharma S; Khuller GK
Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle encapsulated lipopeptide conjugate of antitubercular drug isoniazid: in vitro intracellular activity and in vivo efficacy in a Guinea pig model of tuberculosis.
Horváti K; Bacsa B; Kiss E; Gyulai G; Fodor K; Balka G; Rusvai M; Szabó E; Hudecz F; Bősze S
Bioconjug Chem; 2014 Dec; 25(12):2260-8. PubMed ID: 25394206
[TBL] [Abstract][Full Text] [Related]
19. Acute and subchronic oral toxicity studies in rats with nanoscale and pigment grade titanium dioxide particles.
Warheit DB; Brown SC; Donner EM
Food Chem Toxicol; 2015 Oct; 84():208-24. PubMed ID: 26341192
[TBL] [Abstract][Full Text] [Related]
20. Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis.
Thee S; Detjen AA; Wahn U; Magdorf K
Scand J Infect Dis; 2010 Apr; 42(4):294-8. PubMed ID: 20100111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
